Primary sclerosing cholangitis;Colangitis esclerosante primaria

Gastroenterologia y Hepatologia

Volumn 27, Issue 9, 2004, Pages 545-551

  Pares A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CIPROFLOXACIN; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; METHOTREXATE; METRONIDAZOLE; MITOCHONDRION ANTIBODY; MUSCLE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; NICOTINE; NORFLOXACIN; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ANTIBIOTIC THERAPY; ANTIBODY TITER; BILE DUCT CARCINOMA; CLINICAL FEATURE; CLINICAL PROTOCOL; CYTOKINE PRODUCTION; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEREDITY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; REVIEW;

EID: 9744232918     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13068141     Document Type: Review

References (75)

1. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
2. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Prac Clin Res Gastroenterol 2001;15:553-62.
3. Escorsell A, Parés A, Rodés J, Solis-Herruzo JA, Miras M, De la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol 1994;21:787-91.
4. Boberg KM, Aadland C, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
5. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;126:1364-9.
6. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
7. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Sem Liv Dis 1991;11:31-9.
8. Mason AL, Xu L, Guo L, Garry RF. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998;351:1620-4.
9. Brooke BN, Dykes PW, Walker FC. A study of liver disorder in ulcerative colitis. Postgrad Med J 1961;37:245-51.
10. Olsson R, Bjornsson E, Backman L, Friman S, Hockerstetd K, Kaijser B, et al. Bile duct bacterial isolates in PSC: a study of explanted livers. J Hepatol 1998;28:426-32.
11. Vierling J. Aetiopathogenesis of primary sclerosing cholangitis. En: Manns P, Chapman RW, Stiehl A, Wiesner R, editors. Primary sclerosing cholangitis. London: Kluwer Academic Publishers, 1998; p. 37-45.
12. Mitchell SA, Thyssen M, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002;51:567-73.
13. Chapman RW, Varghese Z, Gaul R, Patel G, Kininon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.
14. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990;322:1842-4.
15. Zetterquist H, Broome U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in swedish patients with sclerosing cholangitis. Gut 1992;33:942-6.
16. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballería L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459-69.
17. Mitchell SA, Grove J, Spurkland A, Boberg KM, Fleming KA, Day CP, et al. Association of the TNFα-308 but not the interleukin-10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-94.
18. Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) incfluences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001;121:124-30.
19. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann B, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100: 1710-7.
20. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430-6.
21. Porayto MK, Wiesner RH, LaRusso NF, Ludwig J, MacCarty RL, Steiner BL, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594-602.
22. Broome U, Olsson R, Loof L, Hultcrantz R, Danielsson A, Bodemar G, et al. Natural history and prognostic factors in 305 swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610-5.
23. Boberg KM, Rocca G, Egeland T, Bergquist A, Broome U, Caballería L, et al. Time-dependent cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002;35:6512-657.
24. Terjung B, Spoengler U, Sauerbruch T, Worman HJ. Atypical p-ANCA in IBD and hepatobiloary dosorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000;119:310-22.
25. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct sclerosing cholangitis: a long-term follow-up. Hepatology 2002;35:1494-500.
26. Broome U, Glaumann H, Lindstöm E, Loof L, Almer S, Prytz H, et al. Natural history and outcome in 32 swedish patiens with small duct primary sclerosing cholangitis (SPC). J Hepatol 2002;36:586-9.
27. Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51: 731-5.
28. Chapman RW. Small duct primary sclerosing cholangitis. J Hepatol 2002;36:692-4.
29. Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001;15:681-90.
30. Wilschanski M, Chait P, Wade JA, Davis L, Corey M, StLouis P, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-22.
31. Ernst O, Asselah T, Talbodec N, Sergent G. MR cholangiopancreatography: a promising new tool for diagnosing primary sclerosing cholangitis. AJR Am J Roentgenol 1997;168:1115-6.
32. Ito K, Mitchell DG, Outwater EK, Blasbalg R. Primary sclerosing cholangitis: MR imaging features. AJR Am J Roentgenol 1999;172:1527-33.
33. Jeffrey GP, Reed WD, Carrello D, Shilkin KB. Histological and immunohistochemical study of the gallbladder lesion in primary sclerosing cholangitis. Gut 1991;32:424-9.
34. Vitellas KM, El-Dieb A, Vaswani KK, Bennett WF, Tzalonikou M, Mabee C, et al. MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. AJR Am J Roentgenol 2002;179:399-407.
35. Ludwig J, Barham SS, LaRusso NF, Elbeback LR, Wiesner RH, MCCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981;1:632-40.
36. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003;98:1155-8.
37. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36:1393-9.
38. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997;25:1049-53.
39. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a dutch population. Gut 2002;51:562-6.
40. Feldstein AE, Perrault J, El Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7.
41. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
42. Boberg KM, Bergquist A, Mitchell S, Parés A, Rosina F, Broome U, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11.
43. Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. Primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002;97:1138-42.
44. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
45. Campbell WL, Ferris JV, Holbert BL, Thaete FL, Baron RL. Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US, and MR imaging. Radiology 1998;207:41-50.
46. Keiding S, Hansen S, Rasmussen H, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700-6.
47. Ramage J, Donaghy A, Farrant J, Iorns R, Williams R. Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-9.
48. Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999;30:669-73.
49. Rabinovitz M, Zajko A, Hassanein T, Shetty B, Bron KM, Schade RR, et al. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology 1990;12:747-52.
50. Boberg K, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 2000;32:374-80.
51. Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002;97:528-34.
52. Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2268-74.
53. Parés A, Cisneros L, Salmerón JM, Caballería A, Mas A, Torras A, et al. Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrosis. J Hepatol 2002;36(Suppl 1):155.
54. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
55. Mitchell SA, Bansi D, Hunt N, Christie J, Fleming K, Chapman R. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
56. Harnois DM, Angulo P, Jorgensen RA, LaRusso N, Lindor KD. High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96: 1164-9.
57. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
58. Farkkila M, Karkkainen P, Karvonen A, Nuutinen H, Nurmi H, Pikkarainen P. Combination of ursodeoxycholic acid (UDCA) and metronidazole (MTZ) in PSC: reduction of inflammation in liver correlates with the decrease in the new Mayo Risk Score. Gastroenterology 2003;124:A707.
59. Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971;2:663-4.
60. Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199-203.
61. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991;86:57-61.
62. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
63. Wiesner R, Steiner B, LaRusso N. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991;14:A63.
64. Van Thiel DH, Carroll P, Abu-Elmagd K, Rodríguez-Rilo H, Irish W, McMichael J, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
65. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991;86: 546-52.
66. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9.
67. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338-42.
68. Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, Larusso NF, et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999;44:602-7.
69. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36: 151-6.
70. Stielh A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26:560-6.
71. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000;31:291-8.
72. Harrison J, McMaster P. The role of orthotopic liver transplantation in the management of sclerosing cholangitis. Hepatology 1994;20:14-9.
73. Broome U, Eriksson LS. Assessment for liver transplantation in patients with primary sclerosing cholangitis. J Hepatol 1994;20: 654-9.
74. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7.
75. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002;8:575-81.